Guide

Biosimilars pipeline report: A guide for understanding the growing market 

To date, there have been 59 approvals and 41 launches in the U.S. biosimilars market. 
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

To view and read this report, please fill out the form. 

Related resources

Four people standing and conversing in front of a bright window in an office. Two of them hold tablet devices in their hands.

White paper

Adopting a harmonized approach to local PV outsourcing

Report

Market access outlook: 2027 trends in an unpredictable climate
Cell and gene therapy commercialization

Article

Expert insights to help health systems navigate the challenges of CGT readiness